OPTI:Optibiotix was the only double digit loser, dropping by 10% and deepening my losses by about £2,000 to £4,430. I kept topping up over the last few months at what I thought were stupidly cheap prices, only for them to get even cheaper. After nearly 2 years of frustration, today has just about pushed me to the edge of my patience. I know this is a great company, I know that profits are about to appear, I know there are free shares in SBTX:Skinbiotherapeutics coming soon, and I know Sweetbiotix will be utterly massive. That doesn't take away the hurt of these short term losses, or the knowledge that someone could stroll up today and get a massive load cheaper than any I've bought and reap all the same rewards without the 2 years of anguish.
Never mind eh...
There were a few other biggish losers, with TND:Tandem Group dropping 8% on no volume whatsoever, and more painfully AMYT:Amryt Pharma dropping 6% which was a significant contributor to this week's losses
One bit of great news was TRX:Tissue Regenix finally woke up and climbed 13%. This is still down by 30% but there may be some momentum now after buying out an American (profit-making) company.
Share of the Week should come as no surprise. IQE:IQE is utterly wonderful, with the SIPP holding increasing in value by 46% to go 172% up, and even more impressive was the ISA holding, increasing in value by 74% and now up by 334% on the purchase price. Combined paper profits are now £11,082 and are single-handedly saving my portfolio performance.
Cost price goes up but value doesn't. Where the hell would I be without IQE:IQE?!
Here's the performance of the ISA and share accounts
| Weekly Change | |||
| Portfolio cost | £46,796.25 | +£549.57 | |
| Portfolio sell value (bid price - commission) | £45,983.45 | (-1.7%) | -£1,119.76 |
| Potential profits | £7,757.40 | +£493.28 | |
| Yr 3 Dividends | £0 | +£0 | |
| Yr 3 Profit from sales | £549.25 | +£549.25 | |
| Yr 3 Average monthly cash profit | £2,185.02 | (56%) | +£2,185.02 |
| Total Dividends | £1,179.05 | +£0 | |
| Total Profit from sales | £7,261.74 | +£549.24 | |
| Average monthly cash profit | £344.00 | (8.8%) | +£19.57 |
| (Sold stocks profit + Dividends - Fees / Months) |
A somewhat complex picture! Portfolio cost increased by £549.57 after re-investing the proceeds from selling GVC:GVC Holdings, which I'm slightly relieved to say have crashed by 37p a share since I sold them. If you take that out of the picture, the portfolio value dropped by £1,119.76 mostly thanks to OPTI:Optibiotix and AMYT:Amryt Pharma. The increased profits of IQE:IQE helped prop things up, with potential profits climbing by £493 but it would have been double if I hadn't sold GVC:GVC Holdings despite their drop, and even more if AMYT:Amryt Pharma hadn't dropped by 6%.
This is week 1 of year 3 so we start again from scratch, and if all 52 weeks are like this week I'll be making £2,185 a month. That certainly won't happen but it gives me a massive buffer before I need to sell anything in order to stay at my 10% forecast target. Overall profits increased by £19 a month and take me to 8.8%. When I first sold GVC:GVC Holdings I thought my performance had increased to 9.8%, but I stupidly did the calculation before buying the new shares, which increased the size of the portfolio by over £4,000 and corrected the performance figure. It's still 0.4% better than last week though. Unfortunately these accounts have dropped back into the red by £614.
I really hope this doesn't do another one of those nose-dives for the next few weeks.
Here's the SIPP performance after week 89
| Weekly Change | |||
| Portfolio cost | £17,853.50 | +£0 | |
| Portfolio sell value (bid price - commission) | £21,734.28 | (21.7%) | +£600.32 |
| Potential profits | £6,244.85 | +£1,118.18 | |
| Yr 2 Dividends | £294.96 | +£0 | |
| Yr 2 Profit from sales | £1,596.81 | +£0 | |
| Yr 2 Average monthly cash profit | £213.80 | (14.4%) | -£6.93 |
| Total Dividends | £708.15 | +£0 | |
| Total Profit from sales | £3,946.67 | +£0 | |
| Average monthly cash profit | £220.95 | (14.9%) | -£2.91 |
| (Sold stocks profit + Dividends - Fees / Months) |
Good old SIPP. The exposure to OPTI:Optibiotix isn't as great, so although the increase in potential profits of £1,118 was almost halved by the deepening losses, everything still looks very healthy.
Big wide gap of loveliness.
The poxy tradng account looks like this after week 55
| Weekly Change | |||
| Portfolio cost | £486.05 | +£0 | |
| Cash | £79.63 | +£0 | |
| Portfolio sell value (bid price - commission) | £327.21 | (-32.5%) | +£5.56 |
| Potential profits | £0 | +£0 | |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£22.85 | +£0 | |
| Average monthly cash profit | -£1.71 | (-4.2%) | +£0.03 |
| (Sold stocks profit + Dividends - Fees / Months) |
I suppose I should add year 2 figures into here, but I really couldn't be arsed. A 2p share price increase for REDS:RedstoneConnect reduced the losses by a fiver - yippee!
Hrumph.
Right - I've had enough - well done IQE:IQE you are wonderful. Bad, naughty OPTI:Optibiotix you are in the dog house tonight. Please, please, please, please, please give us some news next week that turns the share price around...
No comments:
Post a Comment